The TB laboratory of the future: macrophage based selection of XDR-TB therapeutics

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Therapy of multidrug-resistant (MDR)-TB is highly problematic; that of extensively drug-resistant (XDR)-TB even more so. Both infections result in high mortality, especially if the patient is coinfected with HIV or presents with AIDS. Selection of therapy for these infections is limited and, for most situations, it is performed 'blind'. However, there is a solution for the selection of effective therapy and this is presented herein. Ideal therapy of the patient infected with MDR-TB or XDR-TB can be determined a priori by the mycobacteriology laboratory. This would involve the isolation of the patient's macrophages, the phagocytosis of the mycobacterial isolate and the presentation of the antitubercular agent to the macrophage-bacterium complex. This system is reviewed in its entirety and its potential and feasibility are supported by hard experimental demonstrations.

Original languageEnglish
Pages (from-to)135-144
Number of pages10
JournalFuture Microbiology
VolumeVol. 3
Issue numbern.º 2
Publication statusPublished - Apr 2008


  • Derivatives
  • K inhibition
  • Macrophages
  • MDR-TB
  • Mycobacterium tuberculosis
  • Phenothiazines
  • Thioridazine
  • XDR-TB


Dive into the research topics of 'The TB laboratory of the future: macrophage based selection of XDR-TB therapeutics'. Together they form a unique fingerprint.

Cite this